Recombinant Anti-IGF1 antibody [EPR5098(2)] - BSA and Azide free (ab221958)
- Datasheet
- References
- Protocols
Overview
-
Product name
Anti-IGF1 antibody [EPR5098(2)] - BSA and Azide free
See all IGF1 primary antibodies -
Description
Rabbit monoclonal [EPR5098(2)] to IGF1 - BSA and Azide free -
Host species
Rabbit -
Tested applications
Suitable for: ELISA, WBmore details
Unsuitable for: IHC-P or IP -
Species reactivity
Reacts with: Recombinant fragment
Predicted to work with: Human
-
Immunogen
Synthetic peptide within Human IGF1 aa 50-150. The exact sequence is proprietary.
Database link: P05019 -
Positive control
- IGF1 recombinant protein
-
General notes
ab221958 is the carrier-free version of ab133542 This format is designed for use in antibody labeling, including fluorochromes, metal isotopes, oligonucleotides, enzymes.
Our carrier-free formats are supplied in a buffer free of BSA, sodium azide and glycerol for higher conjugation efficiency.
Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with <1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Ab221958 is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm.
Maxpar® is a trademark of Fluidigm Canada Inc.
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at -20°C. Stable for 12 months at -20°C. -
Dissociation constant (KD)
KD = 4.20 x 10 -11 M Learn more about KD -
Storage buffer
Constituent: PBS -
Carrier free
Yes -
Concentration information loading... -
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPR5098(2) -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Conjugation kits
-
Recombinant Protein
Applications
Our Abpromise guarantee covers the use of ab221958 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Abreviews | Notes |
|---|---|---|
| ELISA | Use at an assay dependent concentration. | |
| WB | Use at an assay dependent concentration. Predicted molecular weight: 22 kDa. Tested with recombinant protein. |
Target
-
Function
The insulin-like growth factors, isolated from plasma, are structurally and functionally related to insulin but have a much higher growth-promoting activity. May be a physiological regulator of [1-14C]-2-deoxy-D-glucose (2DG) transport and glycogen synthesis in osteoblasts. Stimulates glucose transport in rat bone-derived osteoblastic (PyMS) cells and is effective at much lower concentrations than insulin, not only regarding glycogen and DNA synthesis but also with regard to enhancing glucose uptake. -
Involvement in disease
Defects in IGF1 are the cause of insulin-like growth factor I deficiency (IGF1 deficiency) [MIM:608747]. IGF1 deficiency is an autosomal recessive disorder characterized by growth retardation, sensorineural deafness and mental retardation. -
Sequence similarities
Belongs to the insulin family. -
Cellular localization
Secreted. - Information by UniProt
-
Database links
- Entrez Gene: 3479 Human
- Omim: 147440 Human
- SwissProt: P05019 Human
- Unigene: 160562 Human
-
Form
There are 2 isoforms produced by alternative splicing. Isoform 1 also known as: IGF-IB; Isoform 2 also known as: IGF-IA. -
Alternative names
- IBP1 antibody
- IGF I antibody
- IGF IA antibody
see all
Datasheets and documents
References
ab221958 has not yet been referenced specifically in any publications.
